Moderna Company Insiders
MRNA Stock | USD 34.62 0.32 0.93% |
Moderna employs about 5.8 K people. The company is managed by 24 executives with a total tenure of roughly 13534 years, averaging almost 563.0 years of service per executive, having 241.67 employees per reported executive. Analysis of Moderna's management performance can provide insight into the company performance.
Moderna |
Moderna's latest congressional trading
Congressional trading in companies like Moderna, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Moderna by those in governmental positions are based on the same information available to the general public.
2025-02-13 | Representative Julie Johnson | Acquired Under $15K | Verify | ||
2024-10-08 | Representative Ro Khanna | Acquired Under $15K | Verify |
Moderna Management Team Effectiveness
The company has return on total asset (ROA) of (0.1514) % which means that it has lost $0.1514 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2877) %, meaning that it created substantial loss on money invested by shareholders. Moderna's management efficiency ratios could be used to measure how well Moderna manages its routine affairs as well as how well it operates its assets and liabilities.Moderna Workforce Comparison
Moderna is regarded second in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 16,520. Moderna totals roughly 5,800 in number of employees claiming about 35% of equities under Health Care industry.
The company has Profit Margin (PM) of (1.1) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.29) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.29. Moderna Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Moderna insiders, such as employees or executives, is commonly permitted as long as it does not rely on Moderna's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Moderna insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Stephane Bancel over two weeks ago Acquisition by Stephane Bancel of 357065 shares of Moderna at 30.96 subject to Rule 16b-3 | ||
Hoge Stephen over a month ago Acquisition by Hoge Stephen of 523 shares of Moderna subject to Rule 16b-3 | ||
James Mock over two months ago Disposition of 1453 shares by James Mock of Moderna subject to Rule 16b-3 | ||
Noubar Afeyan over six months ago Disposition of 2100 shares by Noubar Afeyan of Moderna at 121.5699 subject to Rule 16b-3 | ||
Noubar Afeyan over six months ago Disposition of 7996 shares by Noubar Afeyan of Moderna at 122.0689 subject to Rule 16b-3 | ||
James Mock over six months ago Disposition of 705 shares by James Mock of Moderna at 101.9281 subject to Rule 16b-3 |
Moderna Notable Stakeholders
A Moderna stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Moderna often face trade-offs trying to please all of them. Moderna's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Moderna's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Shannon Klinger | Chief Secretary | Profile | |
Brad Miller | Chief Officer | Profile | |
Melanie MBA | Chief Officer | Profile | |
James Mock | Chief Officer | Profile | |
Stephane Bancel | CEO Director | Profile | |
John Reynders | Chief Officer | Profile | |
Ruchi Jain | Principal Scientist | Profile | |
Dave Johnson | Chief Officer | Profile | |
Lavina CFA | Senior Relations | Profile | |
Melissa Moore | Chief Board | Profile | |
Noubar Afeyan | Independent CoFounder | Profile | |
Stephen MD | President | Profile | |
Shannon JD | Chief Secretary | Profile | |
Allison MD | Senior Development | Profile | |
Colleen Hussey | Senior Communications | Profile | |
Patrick Bergstedt | Senior Vaccines | Profile | |
Tracey Franklin | Chief Officer | Profile | |
Michelle Hall | Principal Chemistry | Profile | |
Phil White | Vice Management | Profile | |
Lori Panther | Infectious Development | Profile | |
Jerh Collins | Chief Officer | Profile | |
Juan Andres | Pres Expansion | Profile | |
Charbel MPH | Senior Science | Profile | |
MD FAAP | Senior Development | Profile |
About Moderna Management Performance
The success or failure of an entity such as Moderna often depends on how effective the management is. Moderna management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Moderna management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Moderna management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Moderna operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3700 people.
Please note, the presentation of Moderna's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Moderna's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Moderna's management manipulating its earnings.
Moderna Workforce Analysis
Traditionally, organizations such as Moderna use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Moderna within its industry.Moderna Manpower Efficiency
Return on Moderna Manpower
Revenue Per Employee | 557.9K | |
Revenue Per Executive | 134.8M | |
Net Loss Per Employee | 614K | |
Net Loss Per Executive | 148.4M | |
Working Capital Per Employee | 1M | |
Working Capital Per Executive | 245.5M |
Complementary Tools for Moderna Stock analysis
When running Moderna's price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
FinTech Suite Use AI to screen and filter profitable investment opportunities |